If you are planning a research project and would like to use the biobank’s materials, contact us (see contact information) and tell us about your research design.
On the basis of our discussion, we will conduct a preliminary sample and data search.
The Scientific Steering Committee evaluates especially:
The Scientific Steering Committee may request that the application be supplemented with a statement by a regional ethics committee, as referred to in the Medical Research Act, or other additional statements. Any research carried out by the biobank itself is also evaluated according to the same criteria.
Chairman: Matti Laato (VSSHP), Kirurgia
vice Heikki Irjala
Presenting Official: Lila Kallio, Auria Biopankki
Secretary: Aulikki Santavuori, Auria Biopankki
Klaus Elenius (TY), Lääketieteellinen biokemia (vice prof. Kati Elima)
Laura Pirilä (TY), dos.
Ilmo Leivo (TY), Patologia (varalla dos. Pekka Taimen)
Jorma Toppari (VSSHP), Lastentaudit (vice prof. Harri Niinikoski)
Henna Karra (SatSHP), Patologia (vice Hannu Järveläinen (SatSHP), Sisätaudit)
Antti Jekunen (VSHP), Onkologia (vice Carl-Marcus Svartbäck, patologia)
Veikko Launis (TY), Lääketieteellinen etiikka
Tom Southerington (VSSHP), Tutkimuslakimies (vice Jari-Pekka Tuominen)
Veli-Matti Kähäri (TY), Prof.
Last day to submit material in parentheses
27th of August (13th of August)
24th of September (10th of September)
22th of October (8th of October)
19rd of November (5th of November)
10st of Decembver (26th of November)
Pursuant to the Biobank Act, Auria Biobank can restrict access to samples and data, especially if
Following a positive decision on the assignment of samples and data, a preliminary meeting with the applicant is arranged to agree on the details of how the project will be implemented and to provide a preliminary cost assessment.
A Material Transfer Agreement (MTA) concerning the assignment of samples and data is drawn up together with the researcher’s background organisation, and the costs are confirmed. The background organisation may be a Finnish or international research institution or company.
After signing the MTA, the samples and data can be handed over.
When the research ends, the results of the sample analysis and/or raw data is returned to the biobank in accordance with what is specified in the MTA.
The results of the research must also be published, depending on the research, for example in a scientific magazine.
The biobank assigns samples, research data gained from samples, and health data related to the donor for high-level health sciences research and product development. Written agreements concerning the assignment of samples and data are always concluded with the researcher’s background organisation. The background organisation may be a Finnish or international research institution or company in the sector.
As a rule, the assignment of samples and data takes place such that an individual cannot be identified from them. When it is necessary to link sample data to, e.g., register data, this is carried out by the biobank. The assignment of samples and data requires a supporting statement from the Scientific Steering Committee that monitors the biobank’s research activities, a positive decision from the biobank on the assignment, and an agreement on the terms and conditions of the assignment.
By order of the biobank, the researcher must submit the raw data collected during the research or the sample-specific analysis results to the biobank. The biobank enters the data in its sample and data registers, from where it can be assigned for other research purposes in future. If the donor so wishes and if the research data is of a sufficient standard, the research data can also be made available to the sample donor or the health-care unit treating the donor.
The biobank can also conduct research of its own, participate in research collaboration or employ external service providers for the processing and analysis of samples.